Europe dPCR and qPCR Market Forecast to 2030 - Regional Analysis - By Treatment, Product, Application, and End User

The Europe dPCR and qPCR market was valued at US$2.57 billion in 2022 and is expected to reach US$5.18 billion by 2030; it is estimated to grow at a CAGR of 9.1% from 2022 to 2030.

Increasing Incidence of Genetic and Infectious Diseases Drive Europe dPCR and qPCR Market

According to the National Organization's information on genetic conditions or congenital disabilities, though individual genetic disorders are rare, collectively, they comprise over 15,500 people diagnosed with genetic disorders. In June 2020, as per Novartis AG (Switzerland) report, ~15,000 individuals have sickle cell disease, and 270 newborns are diagnosed with the condition every year. The COVID-19 outbreak had a significant effect on the polymerase chain reaction market growth. The growing demand in the clinical diagnostic market has a favorable effect on the PCR industry. Nearly all diagnostic tests use RT-PCR to test the people having symptoms of COVID-19 and were urged by healthcare experts to undergo a diagnostic test, while the authorities have not endorsed viral culture tests. The majority of biotech and pharmaceutical businesses were concentrating their efforts on research and development divisions to find novel compounds or therapy approaches for COVID-19. In February 2022, Roche added the Cobas 5800 System, a newly released molecular laboratory instrument, to its COVID-19 PCR portfolio for use in nations that accept the CE certification. These product include the cobas SARS-CoV-2 and influenza A/B tests, as well as the cobas SARS-CoV-2 qualitative test. By offering uniform performance and efficiency across low-, medium--, and high-volume molecular laboratory testing needs, these products broaden the Roche Diagnostics molecular portfolio offering. Additionally, healthcare organizations with limited space or resources can have comprehensive access owing to the new, compact Cobas 5800 System. Better testing accessibility will result from this in nations or settings where larger equipment cannot be accommodated due to a lack of resources or space. Thus, increasing incidence of genetic and infectious diseases in which dPCR and qPCR techniques can be used for diagnosis and treatments support the growth of the Europe dPCR and qPCR market.

Europe dPCR and qPCR Market Overview

The European dPCR and qPCR market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Government and private funding for advanced research, the launch of innovative technologies for artificial DNA synthesis, and an increase in various research for novel technology-based applications are likely to be the major factors driving the growth of this market in Europe. In addition, efforts taken by the national governments to encourage innovation through incentive provisions and tax exemption for R&D and new biotech startups are expected to favor the European dPCR and qPCR market growth over the forecast years. However, the effect of Brexit on the European Union may lead to the loss of various alliances, partnerships, ventures, and collaborations, negatively impacting the European dPCR and qPCR market.

Europe dPCR and qPCR Market Segmentation

The Europe dPCR and qPCR market is segmented based on treatment, product, application, end user, and country.

Based on treatment, the Europe dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held a larger share in 2022.

By product, the Europe dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share in 2022.

By application, the Europe dPCR and qPCR market is segmented into research application, clinical application, and forensic application. The clinical application segment held the largest share in 2022. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious disease testing, and other applications.

By end user, the Europe dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held the largest share in 2022.

Based on country, the Europe dPCR and qPCR market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe dPCR and qPCR market in 2022.

Abbott Laboratories, Thermo Fisher Scientific Inc, Takara Bio Inc, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc are some of the leading companies operating in the Europe dPCR and qPCR market.